27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
This study explored the views and experiences of Australians living with dementia relating to voluntary assisted dying (VAD) as an end-of-life care option. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
For people with dementia (n = 6), readiness was facilitated by a desire for autonomy. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The overall advance care planning behavioural intention was at a moderately high level. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Appendix B. Coding tree of main categories and specific sub categories describing factors influencing readiness for advance care planning among people with dementia, family caregivers, and healthcare professionals. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Appendix A. Interview guides on experiences with advance care planning, factors influencing readiness for advance care planning, and the use of conversation aids among people with dementia, family caregivers, and healthcare professionals. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The recent approval of disease-modifying therapies (DMTs) for early Alzheimer's disease (AD) marks a major shift in clinical practice. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This multisite initiative demonstrated that structured PPI is feasible in LMICs when supported by cultural adaptation, PPI coordinator roles, and tailored training for contributors and researchers. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
In this update, we discuss the use of real-world data in the Haute Autorité de Santé assessment of economic evaluations, review how real-world evidence is supporting regulatory approvals in multiple myeloma, and consider lessons from the failed EVOKE trials of semaglutide in Alzheimer's disease for the broader application of target trial emulation. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Down syndrome (DS), caused by trisomy of chromosome 21, is characterized by early-onset oxidative stress, impaired neuronal development, and an increased risk of Alzheimer's disease (AD)-like neuropathology. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Neighborhood disadvantage is a risk factor for dementia, but the mechanisms involved are not well understood. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The model achieved and AUC of 0.72 [0.64, 0.81]. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A Doença de Alzheimer (DA) é a principal causa de demência no mundo, caracterizada por processos neurodegenerativos progressivos que comprometem cognição, comportamento e funcionalidade. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Women have twice the dementia risk compared with men. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Theranostics—the use of diagnostic and therapeutic drugs that target the same molecular marker of disease—extends beyond the paradigm of radiopharmaceutical drug pairs used in oncologic settings (e.g., somatostatin receptor subtype 2 and prostate-specific membrane antigen theranostics) to other 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) is characterized by progressive accumulation of amyloid-β (Aβ) peptides, initiating a pathological cascade from soluble monomers to toxic oligomers, protofibrils, fibrils, and ultimately extracellular amyloid plaques that contribute to synaptic dysfunction and neuronal degeneration. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Neurodegenerative diseases are progressive disorders that damage and eventually kill neurons in the central nervous system (CNS). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
5/15 Patient:innen zeigten initial einen visuell negativen Tau-PET Scan zur Baseline, davon konvertierten vier im Follow-up zu einem Tau-positiven Befund. 5 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD) is a progressive brain disorder that leads to memory loss and a gradual decline in thinking and reasoning abilities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Effect size analysis proves the fact that the hybrid model produces statistically significant performance, as well as cases of clinically meaningful improvements over lightweight CNN baselines. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Obstructive sleep apnea (OSA), a prevalent sleep-disordered breathing condition, is increasingly recognized as a modifiable risk factor for cognitive decline and dementia, including Alzheimer’s disease and vascular dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our study is the first one showing that dietary supplements improve cognition and sleep in a mouse model of DS. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Neurodegenerative disorders (NDDs), primarily alzheimer, dementia, parkinson, and rare NDD disease, present an escalating global health crisis, currently affecting over 55 million older adults worldwide. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Tauopathies are characterized by aberrant tau structure and function, which is associated with neurodegenerative dementias, such as Alzheimer's disease, Pick's disease, and frontotemporal dementia, as well as the motor neuron disease amyotrophic lateral sclerosis. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In addition, we found sex-associated changes in the abundances of several proteins previously reported to be involved in tau pathology, such as Reelin, DARPP-32, Zyxin, Tbce, and Gng5, in JNPL3 mice. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Mediterranean diet (MedDiet) is among the most extensively studied dietary patterns and has been consistently associated with reduced risk of all-cause mortality, cardiovascular disease, metabolic disorders, cognitive decline and several types of cancers. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →